Anupam Rama
Stock Analyst at JP Morgan
(3.43)
# 1,003
Out of 4,479 analysts
161
Total ratings
44.79%
Success rate
3.96%
Average return
Main Sectors:
Top Industries:
49 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SAGE Sage Therapeutics | Maintains: Overweight | $28 → $23 | $10.82 | +112.57% | 4 | Jun 20, 2024 | |
| VERA Vera Therapeutics | Maintains: Overweight | $60 → $65 | $34.93 | +86.09% | 5 | May 31, 2024 | |
| SLDB Solid Biosciences | Maintains: Neutral | $12 → $10 | $5.96 | +67.79% | 3 | May 31, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $34 | $20.66 | +64.57% | 6 | May 21, 2024 | |
| RLYB Rallybio | Downgrades: Neutral | n/a | $1.20 | - | 3 | May 15, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $177 → $175 | $154.20 | +13.49% | 9 | May 3, 2024 | |
| KNSA Kiniksa Pharmaceuticals | Maintains: Overweight | $26 → $30 | $18.67 | +60.69% | 2 | May 1, 2024 | |
| DAWN Day One Biopharmaceuticals | Maintains: Overweight | $32 → $36 | $13.46 | +167.46% | 2 | Apr 22, 2024 | |
| CTMX CytomX Therapeutics | Upgrades: Neutral | n/a | $1.32 | - | 3 | Apr 22, 2024 | |
| ANAB AnaptysBio | Maintains: Neutral | $30 → $28 | $23.94 | +16.96% | 5 | Apr 1, 2024 | |
| ANNX Annexon | Maintains: Overweight | $11 → $13 | $4.57 | +184.78% | 3 | Apr 1, 2024 | |
| ORIC ORIC Pharmaceuticals | Maintains: Overweight | $19 → $18 | $7.52 | +139.36% | 2 | Mar 27, 2024 | |
| RAPT RAPT Therapeutics | Maintains: Neutral | $15 → $13 | $2.79 | +365.95% | 6 | Mar 27, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $148 → $158 | $137.49 | +14.92% | 11 | Mar 20, 2024 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $35 → $45 | $24.91 | +80.65% | 5 | Mar 20, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $88 → $92 | $40.96 | +124.61% | 1 | Mar 18, 2024 | |
| FOLD Amicus Therapeutics | Maintains: Overweight | $21 → $19 | $9.85 | +92.89% | 4 | Mar 18, 2024 | |
| NUVL Nuvalent | Maintains: Overweight | $68 → $98 | $73.00 | +34.25% | 4 | Mar 6, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Overweight | $78 → $79 | $34.98 | +125.84% | 7 | Mar 6, 2024 | |
| SWTX SpringWorks Therapeutics | Maintains: Overweight | $73 → $74 | $37.27 | +98.55% | 3 | Mar 6, 2024 | |
| COGT Cogent Biosciences | Maintains: Overweight | $18 → $20 | $8.24 | +142.72% | 2 | Feb 27, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Overweight | $51 → $57 | $33.72 | +69.04% | 4 | Feb 23, 2024 | |
| ALVR AlloVir | Downgrades: Underweight | n/a | $0.74 | - | 2 | Dec 22, 2023 | |
| ZLAB Zai Lab | Maintains: Overweight | $64 → $66 | $17.37 | +279.97% | 8 | Nov 30, 2023 | |
| GTHX G1 Therapeutics | Downgrades: Underweight | n/a | $2.45 | - | 8 | Oct 6, 2023 | |
| OLMA Olema Pharmaceuticals | Maintains: Overweight | $16 → $19 | $10.41 | +82.52% | 2 | Sep 15, 2023 | |
| GBIO Generation Bio Co. | Maintains: Neutral | $8 → $9 | $2.34 | +284.62% | 2 | Aug 16, 2023 | |
| KOD Kodiak Sciences | Downgrades: Underweight | n/a | $2.24 | - | 6 | Jul 25, 2023 | |
| TVTX Travere Therapeutics | Initiates: Overweight | $26 | $8.09 | +221.38% | 1 | Jul 21, 2023 | |
| REPL Replimune Group | Maintains: Overweight | $38 → $50 | $8.37 | +497.37% | 2 | Jun 15, 2023 | |
| ELEV Elevation Oncology | Downgrades: Underweight | n/a | $2.80 | - | 2 | Nov 10, 2022 | |
| ATRA Atara Biotherapeutics | Downgrades: Neutral | $10 | $7.52 | +32.98% | 5 | Jul 13, 2022 | |
| PASG Passage Bio | Downgrades: Neutral | n/a | $1.00 | - | 3 | Mar 8, 2022 | |
| CYTK Cytokinetics | Initiates: Overweight | n/a | $54.84 | - | 1 | Dec 10, 2021 | |
| TBPH Theravance Biopharma | Upgrades: Neutral | n/a | $8.32 | - | 1 | Nov 5, 2021 | |
| VIR Vir Biotechnology | Upgrades: Neutral | n/a | $8.85 | - | 5 | Oct 25, 2021 | |
| PTGX Protagonist Therapeutics | Upgrades: Overweight | n/a | $34.59 | - | 2 | Oct 12, 2021 | |
| ERAS Erasca | Initiates: Overweight | n/a | $2.32 | - | 1 | Aug 10, 2021 | |
| AGIO Agios Pharmaceuticals | Downgrades: Neutral | n/a | $42.05 | - | 2 | Mar 1, 2021 | |
| DYN Dyne Therapeutics | Initiates: Overweight | n/a | $34.65 | - | 1 | Oct 12, 2020 | |
| ITOS iTeos Therapeutics | Initiates: Overweight | n/a | $14.44 | - | 1 | Aug 18, 2020 | |
| ALNY Alnylam Pharmaceuticals | Downgrades: Neutral | n/a | $247.61 | - | 2 | May 7, 2020 | |
| YMAB Y-mAbs Therapeutics | Initiates: Overweight | n/a | $11.37 | - | 1 | Dec 24, 2019 | |
| DVAX Dynavax Technologies | Upgrades: Overweight | n/a | $11.08 | - | 2 | May 10, 2018 | |
| CLSD Clearside Biomedical | Maintains: Overweight | n/a | $1.23 | - | 2 | Mar 6, 2018 | |
| IFRX InflaRx | Initiates: Overweight | n/a | $1.73 | - | 1 | Dec 4, 2017 | |
| PTCT PTC Therapeutics | Upgrades: Neutral | n/a | $30.39 | - | 2 | Nov 16, 2017 | |
| IRWD Ironwood Pharmaceuticals | Downgrades: Neutral | n/a | $6.22 | - | 1 | Jul 21, 2017 | |
| ARRY Array Technologies | Upgrades: Overweight | n/a | $9.63 | - | 1 | May 3, 2017 |
Sage Therapeutics
Jun 20, 2024
Maintains: Overweight
Price Target: $28 → $23
Current: $10.82
Upside: +112.57%
Vera Therapeutics
May 31, 2024
Maintains: Overweight
Price Target: $60 → $65
Current: $34.93
Upside: +86.09%
Solid Biosciences
May 31, 2024
Maintains: Neutral
Price Target: $12 → $10
Current: $5.96
Upside: +67.79%
Syndax Pharmaceuticals
May 21, 2024
Maintains: Overweight
Price Target: $34
Current: $20.66
Upside: +64.57%
Rallybio
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.20
Upside: -
Sarepta Therapeutics
May 3, 2024
Maintains: Overweight
Price Target: $177 → $175
Current: $154.20
Upside: +13.49%
Kiniksa Pharmaceuticals
May 1, 2024
Maintains: Overweight
Price Target: $26 → $30
Current: $18.67
Upside: +60.69%
Day One Biopharmaceuticals
Apr 22, 2024
Maintains: Overweight
Price Target: $32 → $36
Current: $13.46
Upside: +167.46%
CytomX Therapeutics
Apr 22, 2024
Upgrades: Neutral
Price Target: n/a
Current: $1.32
Upside: -
AnaptysBio
Apr 1, 2024
Maintains: Neutral
Price Target: $30 → $28
Current: $23.94
Upside: +16.96%
Annexon
Apr 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $4.57
Upside: +184.78%
ORIC Pharmaceuticals
Mar 27, 2024
Maintains: Overweight
Price Target: $19 → $18
Current: $7.52
Upside: +139.36%
RAPT Therapeutics
Mar 27, 2024
Maintains: Neutral
Price Target: $15 → $13
Current: $2.79
Upside: +365.95%
Neurocrine Biosciences
Mar 20, 2024
Maintains: Overweight
Price Target: $148 → $158
Current: $137.49
Upside: +14.92%
BridgeBio Pharma
Mar 20, 2024
Maintains: Overweight
Price Target: $35 → $45
Current: $24.91
Upside: +80.65%
Ultragenyx Pharmaceutical
Mar 18, 2024
Maintains: Overweight
Price Target: $88 → $92
Current: $40.96
Upside: +124.61%
Amicus Therapeutics
Mar 18, 2024
Maintains: Overweight
Price Target: $21 → $19
Current: $9.85
Upside: +92.89%
Nuvalent
Mar 6, 2024
Maintains: Overweight
Price Target: $68 → $98
Current: $73.00
Upside: +34.25%
Apellis Pharmaceuticals
Mar 6, 2024
Maintains: Overweight
Price Target: $78 → $79
Current: $34.98
Upside: +125.84%
SpringWorks Therapeutics
Mar 6, 2024
Maintains: Overweight
Price Target: $73 → $74
Current: $37.27
Upside: +98.55%
Cogent Biosciences
Feb 27, 2024
Maintains: Overweight
Price Target: $18 → $20
Current: $8.24
Upside: +142.72%
IDEAYA Biosciences
Feb 23, 2024
Maintains: Overweight
Price Target: $51 → $57
Current: $33.72
Upside: +69.04%
AlloVir
Dec 22, 2023
Downgrades: Underweight
Price Target: n/a
Current: $0.74
Upside: -
Zai Lab
Nov 30, 2023
Maintains: Overweight
Price Target: $64 → $66
Current: $17.37
Upside: +279.97%
G1 Therapeutics
Oct 6, 2023
Downgrades: Underweight
Price Target: n/a
Current: $2.45
Upside: -
Olema Pharmaceuticals
Sep 15, 2023
Maintains: Overweight
Price Target: $16 → $19
Current: $10.41
Upside: +82.52%
Generation Bio Co.
Aug 16, 2023
Maintains: Neutral
Price Target: $8 → $9
Current: $2.34
Upside: +284.62%
Kodiak Sciences
Jul 25, 2023
Downgrades: Underweight
Price Target: n/a
Current: $2.24
Upside: -
Travere Therapeutics
Jul 21, 2023
Initiates: Overweight
Price Target: $26
Current: $8.09
Upside: +221.38%
Replimune Group
Jun 15, 2023
Maintains: Overweight
Price Target: $38 → $50
Current: $8.37
Upside: +497.37%
Elevation Oncology
Nov 10, 2022
Downgrades: Underweight
Price Target: n/a
Current: $2.80
Upside: -
Atara Biotherapeutics
Jul 13, 2022
Downgrades: Neutral
Price Target: $10
Current: $7.52
Upside: +32.98%
Passage Bio
Mar 8, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.00
Upside: -
Cytokinetics
Dec 10, 2021
Initiates: Overweight
Price Target: n/a
Current: $54.84
Upside: -
Theravance Biopharma
Nov 5, 2021
Upgrades: Neutral
Price Target: n/a
Current: $8.32
Upside: -
Vir Biotechnology
Oct 25, 2021
Upgrades: Neutral
Price Target: n/a
Current: $8.85
Upside: -
Protagonist Therapeutics
Oct 12, 2021
Upgrades: Overweight
Price Target: n/a
Current: $34.59
Upside: -
Erasca
Aug 10, 2021
Initiates: Overweight
Price Target: n/a
Current: $2.32
Upside: -
Agios Pharmaceuticals
Mar 1, 2021
Downgrades: Neutral
Price Target: n/a
Current: $42.05
Upside: -
Dyne Therapeutics
Oct 12, 2020
Initiates: Overweight
Price Target: n/a
Current: $34.65
Upside: -
iTeos Therapeutics
Aug 18, 2020
Initiates: Overweight
Price Target: n/a
Current: $14.44
Upside: -
Alnylam Pharmaceuticals
May 7, 2020
Downgrades: Neutral
Price Target: n/a
Current: $247.61
Upside: -
Y-mAbs Therapeutics
Dec 24, 2019
Initiates: Overweight
Price Target: n/a
Current: $11.37
Upside: -
Dynavax Technologies
May 10, 2018
Upgrades: Overweight
Price Target: n/a
Current: $11.08
Upside: -
Clearside Biomedical
Mar 6, 2018
Maintains: Overweight
Price Target: n/a
Current: $1.23
Upside: -
InflaRx
Dec 4, 2017
Initiates: Overweight
Price Target: n/a
Current: $1.73
Upside: -
PTC Therapeutics
Nov 16, 2017
Upgrades: Neutral
Price Target: n/a
Current: $30.39
Upside: -
Ironwood Pharmaceuticals
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $6.22
Upside: -
Array Technologies
May 3, 2017
Upgrades: Overweight
Price Target: n/a
Current: $9.63
Upside: -